Niagen Bioscience/$NAGE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
- Ticker
- $NAGE
- Sector
- Consumer Essentials
- Primary listing
- NASDAQ
- Employees
- 117
- Headquarters
- Los Angeles, United States
- Website
- www.niagenbioscience.com
NAGE Metrics
BasicAdvanced
$164M
17.17
$0.12
2.08
-
Price and volume
Market cap
$164M
Beta
2.08
52-week high
$7.28
52-week low
$2.04
Average daily volume
586K
Financial strength
Current ratio
5.927
Quick ratio
4.507
Long term debt to equity
0.015
Total debt to equity
0.025
Profitability
EBITDA (TTM)
3.863
Gross margin (TTM)
63.86%
Net profit margin (TTM)
8.37%
Operating margin (TTM)
2.28%
Effective tax rate (TTM)
7.37%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
1.69%
Return on equity (TTM)
13.32%
Valuation
Price to earnings (TTM)
17.166
Price to revenue (TTM)
1.347
Price to book
1.97
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
35.966
Free cash flow yield (TTM)
2.78%
Free cash flow per share (TTM)
0.058
Growth
Revenue change (TTM)
-1.94%
Earnings per share change (TTM)
-48.66%
3-year revenue growth (CAGR)
13.62%
10-year revenue growth (CAGR)
18.94%
3-year earnings per share growth (CAGR)
9.51%
10-year earnings per share growth (CAGR)
6.69%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
Analyst projections of the future price of Niagen Bioscience stock.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
Upcoming events
No upcoming events
NAGE News
AllArticlesVideos
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Business Wire2 weeks ago
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Business Wire3 weeks ago
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Business Wire3 weeks ago
Funds containing NAGE
Fund name | Fund size | $NAGE weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.